(Q45055440)

9 December 2017

title

Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression (English)

1 reference

9 December 2017

1 reference

1 reference

1 reference

Bungo Saito

1

1 reference

9 December 2017

Eisuke Shiozawa

2

1 reference

9 December 2017

Toshiko Yamochi-Onizuka

3

1 reference

9 December 2017

Daisuke Adachi

4

1 reference

9 December 2017

Tsuyoshi Nakamaki

5

1 reference

9 December 2017

Shigeru Tomoyasu

6

1 reference

9 December 2017

Mitsuhiro Omine

7

1 reference

9 December 2017

Toshiyuki Mitsuya

8

1 reference

9 December 2017

Masafumi Takimoto

9

1 reference

9 December 2017

Hidekazu Ota

10

1 reference

9 December 2017

publication date

1 September 2004

1 reference

9 December 2017

published in

Pathology International

1 reference

9 December 2017

volume

54

1 reference

9 December 2017

issue

9

1 reference

9 December 2017

page(s)

667-674

1 reference

Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

Prognostic clinicopathologic factors, including immunologic expression in diffuse large B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2004.01678.X

10.1111/J.1440-1827.2004.01678.X

21 January 2018

Identifiers

DOI

1 reference

9 December 2017

1 reference